Bio-Rad Laboratories, Inc. Announces Commencement of Exchange Offer of Its 8.00% Senior Subordinated Notes Due 2016 for Register
HERCULES, CA -- (Marketwire) -- 12/29/09 --
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced that it has commenced a registered exchange offer to exchange up to $300 million aggregate principal amount of its 8.00% Senior Subordinated Notes due 2016 which have been registered under the Securities Act of 1933, as amended (the "Exchange Notes"), for any and all of its outstanding 8.00% Senior Subordinated Notes due 2016 which were issued in a private placement (the "Private Notes")
The sole purpose of the exchange offer is to fulfill the obligations of Bio-Rad with respect to the registration of the Private Notes. Pursuant to a registration rights agreement entered into by Bio-Rad in connection with the sale of the Private Notes, Bio-Rad agreed to file with the Securities and Exchange Commission a registration statement relating to the exchange offer pursuant to which the Exchange Notes, containing substantially identical terms to the Private Notes, would be offered in exchange for Private Notes that are tendered by the holders of those notes
Any Private Notes not tendered for exchange in the exchange offer will remain outstanding and continue to accrue interest, but will not retain any rights under the registration rights agreement except in limited circumstances
The terms of the exchange offer are contained in the exchange offer prospectus
The exchange offer will expire at 5:00 PM, New York City time, on January 28, 2010, unless extended. Private Notes tendered pursuant to the exchange offer may be withdrawn at any time prior to the expiration date by following the procedures set forth in the exchange offer prospectus
Requests for assistance or for copies of the exchange offer prospectus should be directed to Wells Fargo Bank, National Association, the exchange agent, at 625 Marquette Avenue, MAC CODE: N9303-121, Minneapolis, Minnesota 55402, Attention: Corporate Trust Administration, 800-344-5128
This press release shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities. The exchange offer will be made only by means of a written prospectus
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the exchange offer prospectus and in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K
The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements
For more information contact: Christine Tsingos, Vice President and Chief Financial Officer, or Ron Hutton, Treasurer Bio-Rad Laboratories, Inc
Market Data 
Markets 
AI
